317 related articles for article (PubMed ID: 26433849)
1. Monoclonal Antibodies.
Geskin LJ
Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
3. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of rexinoids.
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Klemke CD; Goerdt S
G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
Foss FM; Waldmann TA
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
[TBL] [Abstract][Full Text] [Related]
7. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
9. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
10. Denileukin diftitox for the treatment of panniculitic lymphoma.
McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio CC; Rook AH
Arch Dermatol; 2002 Jun; 138(6):740-2. PubMed ID: 12056952
[No Abstract] [Full Text] [Related]
11. [Current development of new drugs in malignant lymphoma].
Ogura M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
[No Abstract] [Full Text] [Related]
12. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
14. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Kuzel TM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T-cell lymphoma: Biologic targets for therapy.
Choi J; Foss F
Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
[TBL] [Abstract][Full Text] [Related]
16. Denileukin diftitox and vision loss.
Ruddle JB; Prince HM
Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
[No Abstract] [Full Text] [Related]
17. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
18. New advances in the management of cutaneous T-cell lymphoma.
Young SK
Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
[No Abstract] [Full Text] [Related]
19. Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
[TBL] [Abstract][Full Text] [Related]
20. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
